Qing Liu

Qing Liu

Auto-generated profile, based on publicly available information

Qing Liu

Department of Pathology, The First People’s Hospital of Foshan, Foshan, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2022 in JCO Precision Oncology
Verified
Journal Article
Open access
GCGengxi Cai
Gengxi Cai
ZGZhanwen Guan
Zhanwen Guan
YJYabin Jin
Yabin Jin
ZSZuhui Su
Zuhui Su
XCXiangping Chen
Xiangping Chen
WLWei Luo
Wei Luo
PURPOSE: Neoadjuvant chemotherapy (NAC) has been widely used in patients with breast cancer to minish tumor burden and increase resection rate of cancer. T-cell repertoire has been believed to be able to monitor antitumor immune responses. This study aimed to explore the dynamic change of T-cell repertoire and its clinical value in evaluating the tumor response in patients with breast cancer receiving NAC. MATERIALS AND METHODS: Ninety-four patients who underwent NAC before surgery were recruited, and peripheral blood samples were collected at multiple time points during NAC. High-throughput T-cell receptor (TCR)-β sequencing was used to characterize the T-cell repertoire of every sample and analyzed the changes in circulating T-cell repertoire during NAC. RESULTS: We found that the diversity of TCR repertoires was associated with age and clinical stage of the patients with breast cancer. The distribution of Vβ and Jβ genes in TCR repertoires was skewed in patients with human epidermal growth factor receptor 2–positive (HER2+) breast cancer. Vβ20.1 and Vβ30 expression levels before NAC correlate with tumor response after all cycles of NAC in HER2– and HER2+ patients, respectively. Some CDR3 motifs that correlated with clinical response in either HER2+ or HER2– patients were identified. Besides, TCR repertoire evolved during NAC and the diversity of TCR repertoire decreased more after two cycles of NAC in patients with good tumor response after all cycles of NAC ( P = .0061). CONCLUSION: Our results demonstrated that TCR repertoire correlated with the characteristics of the tumor, such as the expression status of HER2. Moreover, some characteristics of TCR repertoires that correlated with clinical response were identified and they might provide useful information to tailor therapeutic regimens at the early cycle of NAC.

3 November 2025 in Oncogene
Verified
Journal Article
Closed access
PDF file
HHHongbiao Huang
Hongbiao Huang
YXYujie Xiang
Yujie Xiang
YDYuanfei Deng
Yuanfei Deng
QLQing Liu
Qing Liu
GCGengxi Cai
Gengxi Cai
YLYuning Liao
Yuning Liao

7 May 2026 in Oncogene
Verified
Journal Article
Closed access
PDF file
YLYuning Liao
Yuning Liao
WSWenshuang Sun
Wenshuang Sun
YLYuting Li
Yuting Li
YDYuanfei Deng
Yuanfei Deng
QLQing Liu
Qing Liu
HHHongbiao Huang
Hongbiao Huang